COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) are effective at preventing COVID-19-associated hospitalization (1-3). However, how well mRNA vaccines protect against the most severe outcomes of these hospitalizations, including invasive mechanical ventilation (IMV) or death is uncertain. Using a case-control design, mRNA vaccine effectiveness (VE) against COVID-19-associated IMV and in-hospital death was evaluated among adults aged ≥18 years hospitalized at 21 U.S. medical centers during March 11, 2021-January 24, 2022. During this period, the most commonly circulating variants of SARS-CoV-2, the virus that causes COVID-19, were B.1.1.7 (Alpha), B.1.617.2 (Delta), and B.1.1.529 (Omicron). Previous vaccination (2...
In a multi-state network, vaccine effectiveness (VE) against COVID-19 hospitalizations was evaluated...
Objectives: To characterize the clinical severity of covid-19 associated with the alpha, delta, and...
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late D...
BACKGROUND Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) v...
Outcomes of 109 hospitalized COVID-19 patients who received at least one vaccine dose 14 or more day...
What is already known about this topic? mRNA COVID-19 vaccines are effective in preventing severe CO...
BackgroundAs severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination coverage incre...
Importance: A comprehensive understanding of the benefits of COVID-19 vaccination requires consider...
Background: The prioritization of U.S. health care personnel for early receipt of messenger RNA (mR...
BackgroundCoronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were authorized in the U...
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) provide protection again...
Background: As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need...
Monovalent COVID-19 mRNA vaccines, designed against the ancestral strain of SARS-CoV-2, successfully...
Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated ...
Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated ...
In a multi-state network, vaccine effectiveness (VE) against COVID-19 hospitalizations was evaluated...
Objectives: To characterize the clinical severity of covid-19 associated with the alpha, delta, and...
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late D...
BACKGROUND Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) v...
Outcomes of 109 hospitalized COVID-19 patients who received at least one vaccine dose 14 or more day...
What is already known about this topic? mRNA COVID-19 vaccines are effective in preventing severe CO...
BackgroundAs severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination coverage incre...
Importance: A comprehensive understanding of the benefits of COVID-19 vaccination requires consider...
Background: The prioritization of U.S. health care personnel for early receipt of messenger RNA (mR...
BackgroundCoronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were authorized in the U...
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) provide protection again...
Background: As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need...
Monovalent COVID-19 mRNA vaccines, designed against the ancestral strain of SARS-CoV-2, successfully...
Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated ...
Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated ...
In a multi-state network, vaccine effectiveness (VE) against COVID-19 hospitalizations was evaluated...
Objectives: To characterize the clinical severity of covid-19 associated with the alpha, delta, and...
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late D...